Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia

Patients with chronic kidney disease (CKD) have a high risk of hyperkalemia, which increases mortality and can lead to renin–angiotensin–aldosterone system inhibitor (RAASi) dose reduction or discontinuation. Patiromer, a nonabsorbed potassium binder, has been shown to normalize serum potassium in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Bushinsky, David A, Williams, Gordon H, Pitt, Bertram, Weir, Matthew R, Freeman, Mason W, Garza, Dahlia, Stasiv, Yuri, Li, Elizabeth, Berman, Lance, Bakris, George L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678168/
https://www.ncbi.nlm.nih.gov/pubmed/26376130
http://dx.doi.org/10.1038/ki.2015.270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678168/
https://www.ncbi.nlm.nih.gov/pubmed/26376130
http://dx.doi.org/10.1038/ki.2015.270

Ejemplares similares